+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Prospectives in head and neck oncology

Prospectives in head and neck oncology

Journal of Laryngology and Otology 90(3): 221-251

The knowledge that the sensitivity of a tumor to radiotherapy and chemotherapy relates to its cytokinetics led to the adoption of a treatment protocol which it is hoped will expose the tumor cells in a most sensitive phase to a particular form of treatment. An attempt was made to synchronize tumor cells with vincristine for subsequent destruction by bleomycin given 6 h later. After an arbitrary 18 h interval which may approximate the G1 interval in human squamous carcinomas, cells that escaped the effects of vincristine and bleomycin might be destroyed by a cycle specific drug such as cyclophosphamide. This is given as a single large dose and may be omitted in debilitated and elderly patients. Methotrexate is then given as an i.v. infusion over a 24 h period. This prolonged infusion may increase the percentage of cells exposed to the drug during their sensitive S phase. Folinic acid is given for 36 h following the methotrexate infusion to protect the patient's normal stem cell system. Initial radiotherapy in doses of 1500-2000 rads, given over 10 days, may be used to increase the percentage of proliferating cells and radiotherapy may be repeated in the intervals between courses of chemotherapy. A repeated constant cell kill fraction may be achieved in the entire tumor cell population. It is difficult to decide when chemotherapy should stop, as there is no test to indicate the persistence of 0.01% residual viable tumor cells. Maintenance chemotherapy could be continued with benefit for as long as 2 yr. A small mmber of cancer cells may remain viable because of pharmacological barriers, inherent or acquired drug resistance or because environmental factors provided protection against the effects of radiotherapy and chemotherapy. For whatever reason the elimination of this small residual tumor cell population is likely to be successfully managed by a competent immunological system.

(PDF same-day service: $19.90)

Accession: 006206310

Download citation: RISBibTeXText

PMID: 768393

DOI: 10.1017/s0022215100082013

Related references

The organisation of head and neck oncology services in the UK: The Royal College of Surgeons of England and British Association of Head and Neck Oncologists' preliminary multidisciplinary head and neck oncology audit. Annals of the Royal College of Surgeons of England 85(3): 154-157, 2003

Organization of primary care pathway in head and neck oncology (short version): Organization of chemotherapy in head and neck oncology. European Annals of Otorhinolaryngology, Head and Neck Diseases 132(4): 209-212, 2016

Antibodies combined with radiotherapy in the curative treatment of head and neck cancer. Danish Society of Head-Neck Oncology and Danish Head-Neck Cancer Group. Ugeskrift for Laeger 167(12-13): 1391-1391, 2005

New computer based therapeutic possibilities in head and neck cancer. IMRT and CAS. The Danish Society of Head and Neck Oncology. Ugeskrift for Laeger 164(12): 1659-1659, 2002

Technical guidelines for head and neck cancer IMRT on behalf of the Italian association of radiation oncology - head and neck working group. Radiation Oncology 9: 264-264, 2015

From head and neck surgery to head and neck oncology: the disciplinary guarantee for comprehensive cancer therapy. Zhonghua Zhong Liu Za Zhi 31(11): 877-879, 2010

Radiotherapy resources for the care of head and neck patients in Italy. A survey by the head and neck group of the Italian Association for Radiation Oncology (AIRO). Tumori 94(1): 59-64, 2008

French Society of ENT (SFORL) guidelines for care pathway organization in head and neck oncology (short version). Early management of head and neck cancer. European Annals of Otorhinolaryngology, Head and Neck Diseases 132(4): 205-208, 2016

Surgical margin determination in head and neck oncology: current clinical practice. The results of an International American Head and Neck Society Member Survey. Head & Neck 27(11): 952-958, 2005

Oncology of the head-neck region. German Society of Otorhinolaryngology, Head and Neck Surgery. Hno 48(2): 104-118, 2000

Patterns of postoperative radiotherapy for head and neck cancer in Italy: a prospective, observational study by the head and neck group of the Italian Association for Radiation Oncology (AIRO). Tumori 97(2): 170-176, 2011

A phase III randomised trial of cistplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group. British Journal of Cancer 61(2): 311-315, 1990

Head and neck carcinoma in the United States: first comprehensive report of the Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN). Cancer 118(23): 5783-5792, 2013

International Federation of Head Neck Oncology Society 5(th) World Congress/American Head Neck Society 2014 update. Indian Journal of Medical and Paediatric Oncology 35(3): 228-230, 2014

Head and neck cancer. Head and Neck Oncology Workgroup, Legislative Task Force on Cancer in Texas. Texas Medicine 83(9 Pt 2): 4-16, 1987